Daniel Faga Sells 17,679 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 17,679 shares of the business’s stock in a transaction dated Friday, March 27th. The shares were sold at an average price of $61.61, for a total value of $1,089,203.19. Following the completion of the transaction, the chief executive officer owned 495,965 shares in the company, valued at $30,556,403.65. The trade was a 3.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The stock was sold at an average price of $44.71, for a total value of $638,503.51.
• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The shares were sold at an average price of $45.11, for a total value of $415,102.22.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Price Performance

ANAB stock opened at $57.40 on Monday. AnaptysBio, Inc. has a 1-year low of $15.40 and a 1-year high of $68.39. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -110.38 and a beta of 0.32. The business has a 50 day simple moving average of $55.30 and a two-hundred day simple moving average of $43.79.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The business had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. Sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has authorized a share buyback program on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ANAB shares. HC Wainwright lifted their price target on shares of AnaptysBio from $51.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Barclays lifted their target price on AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Truist Financial upgraded AnaptysBio to a “hold” rating in a research report on Wednesday, March 25th. Finally, Wedbush increased their price target on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $78.44.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds have recently bought and sold shares of ANAB. Vanguard Group Inc. lifted its position in AnaptysBio by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after purchasing an additional 67,048 shares during the last quarter. State Street Corp increased its holdings in shares of AnaptysBio by 20.6% in the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after buying an additional 180,042 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after buying an additional 822,975 shares in the last quarter. 683 Capital Management LLC raised its position in shares of AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 101,093 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new position in shares of AnaptysBio in the 4th quarter valued at about $21,559,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.